Opinion | Therese Raphael, Bloomberg | Monday November 23, 2020
Regulatory authorities are gearing up for a deluge in people reporting side effects when the new covid-19 vaccines go into use. Even as vaccines like the one from Pfizer and BioNTech reach safety milestones and look set for regulatory approval, managing the reporting and follow-up of what are known as adverse drug reactions will be critical to keep...
www.ndtv.com